Tumor Biology

, Volume 37, Issue 10, pp 14153–14163 | Cite as

Novel dual-mode nanobubbles as potential targeted contrast agents for female tumors exploration

  • Hengli Yang
  • Tian Zhou
  • Wenbin Cai
  • Xiaomin Yi
  • Xi Liu
  • Yixiao Wang
  • Li Zhang
  • Yunyou Duan
Original Article


The purpose of this study was to prepare tumor-specific dual-mode nanobubbles as both ultrasound contrast agents (UCAs) and near-infrared fluorescence (NIRF) imaging agents for female tumors. Recent studies have demonstrated the conjugation of anti-tumor ligands on the surface of nanobubbles for use as molecule-targeting ultrasound contrast agents for tumor visualization. However, this complicated procedure has also posed a challenge to nanobubble stability. Thus, in the present study, we combined the fluorescent dye, NIRF IR-780 iodide, which has lipid solubility and tumor-targeting characteristics, with the phospholipid film of nanobubbles that we constructed. We then characterized the physical features of the IR-780-nanobubbles, observed their tumor-targeting capacity in multiple female tumor cell types in vitro, and verified their capability for use in tumor-specific ultrasound contrast imaging and NIRF imaging in vivo. The results showed that the new IR-780-nanobubbles had a uniform nano-size (442.5 ± 48.6 nm) and stability and that they were safe and effective at NIRF imaging and ultrasound imaging in vitro. The IR-780-nanobubbles were found to automatically accumulate on different female tumor cells in vitro with a considerable targeting rate (close to 40 %) but did not accumulate on cardiac muscle cells used as a negative control. Importantly, the IR-780-nanobubbles can detect female tumors precisely via dual-mode imaging in vivo. In conclusion, the new dual-mode IR-780-nanobubbles are stable and have potential advantages in non-invasive tumor-specific detection for female tumors via contrast-enhanced ultrasound and NIRF imaging.


IR-780-nanobubbles Dual-mode Tumor-specific Female tumors 



This work was financially supported by the National Natural Science Foundation of China (grant number 81571730). The authors are grateful to the Department of Pharmaceutical Analysis and the Department of Molecular Biology, Fourth Military Medical University for their technical support and kind provision of equipment.

Compliance with ethical standards

Conflicts of interest



  1. 1.
    Nguyen AT, Wrenn SP. Acoustically active liposome-nanobubble complexes for enhanced ultrasonic imaging and ultrasound-triggered drug delivery. Wiley Interdisciplinary Reviews. Nanomedicine Nanobiotechnol. 2014;6:316–25.CrossRefGoogle Scholar
  2. 2.
    Duvshani-Eshet M, Machluf M. Efficient transfection of tumors facilitated by long-term therapeutic ultrasound in combination with contrast agent: from in vitro to in vivo setting. Cancer Gene Ther. 2007;14:306–15.CrossRefPubMedGoogle Scholar
  3. 3.
    Huber PE, Pfisterer P. In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 2000;7:1516–25.CrossRefPubMedGoogle Scholar
  4. 4.
    Mannell H, Pircher J, Rathel T, Schilberg K, Zimmermann K, Pfeifer A, et al. Targeted endothelial gene delivery by ultrasonic destruction of magnetic microbubbles carrying lentiviral vectors. Pharm Res. 2012;29:1282–94.CrossRefPubMedGoogle Scholar
  5. 5.
    Anwer K, Kao G, Proctor B, Anscombe I, Florack V, Earls R, et al. Ultrasound enhancement of cationic lipid-mediated gene transfer to primary tumors following systemic administration. Gene Ther. 2000;7:1833–9.CrossRefPubMedGoogle Scholar
  6. 6.
    Hosseinkhani H, Tabata Y. Ultrasound enhances in vivo tumor expression of plasmid DNA by PEG-introduced cationized dextran. J Control Release. 2005;108:540–56.CrossRefPubMedGoogle Scholar
  7. 7.
    Ferrara KW, Borden MA, Zhang H. Lipid-shelled vehicles: engineering for ultrasound molecular imaging and drug delivery. Acc Chem Res. 2009;42:881–92.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Hobbs SK, Monsky WL, Yuan F, Roberts WG, Griffith L, Torchilin VP, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A. 1998;95:4607–12.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Yin T, Wang P, Zheng R, Zheng B, Cheng D, Zhang X, et al. Nanobubbles for enhanced ultrasound imaging of tumors. Int J Nanomedicine. 2012;7:895–904.PubMedPubMedCentralGoogle Scholar
  10. 10.
    Krupka TM, Solorio L, Wilson RE, Wu H, Azar N, Exner AA. Formulation and characterization of echogenic lipid-Pluronic nanobubbles. Mol Pharm. 2010;7:49–59.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Wang Y, Li X, Zhou Y, Huang P, Xu Y. Preparation of nanobubbles for ultrasound imaging and intracelluar drug delivery. Int J Pharm. 2010;384:148–53.CrossRefPubMedGoogle Scholar
  12. 12.
    Weller GE, Wong MK, Modzelewski RA, Lu E, Klibanov AL, Wagner WR, et al. Ultrasonic imaging of tumor angiogenesis using contrast microbubbles targeted via the tumor-binding peptide arginine-arginine-leucine. Cancer Res. 2005;65:533–9.PubMedGoogle Scholar
  13. 13.
    Stieger SM, Dayton PA, Borden MA, Caskey CF, Griffey SM, Wisner ER, et al. Imaging of angiogenesis using Cadence contrast pulse sequencing and targeted contrast agents. Contrast Media Mol Imaging. 2008;3:9–18.CrossRefPubMedGoogle Scholar
  14. 14.
    Yang H, Cai W, Xu L, Lv X, Qiao Y, Li P, et al. Nanobubble-affibody: novel ultrasound contrast agents for targeted molecular ultrasound imaging of tumor. Biomaterials. 2015;37:279–88.CrossRefPubMedGoogle Scholar
  15. 15.
    Yang X, Shi C, Tong R, Qian W, Zhau HE, Wang R, et al. Near IR heptamethine cyanine dye-mediated cancer imaging. Clin Cancer Res. 2010;16:2833–44.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Bloch M, Jablonowski L, Yavin E, Moradov D, Djavsarov I, Nyska A, et al. Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents. Int J Pharm. 2015;478:504–16.CrossRefPubMedGoogle Scholar
  17. 17.
    Yi X, Wang F, Qin W, Yang X, Yuan J. Near-infrared fluorescent probes in cancer imaging and therapy: an emerging field. Int J Nanomedicine. 2014;9:1347–65.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Ibsen S, Schutt CE, Esener S. Microbubble-mediated ultrasound therapy: a review of its potential in cancer treatment. Drug Des Devel Ther. 2013;7:375–88.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lanza GM, Abendschein DR, Hall CS, Scott MJ, Scherrer DE, Houseman A, et al. In vivo molecular imaging of stretch-induced tissue factor in carotid arteries with ligand-targeted nanoparticles. J Am Soc Echocardiogr. 2000;13:608–14.CrossRefPubMedGoogle Scholar
  20. 20.
    Hughes MS, Marsh JN, Hall CS, Fuhrhop RW, Lacy EK, Lanza GM, et al. Acoustic characterization in whole blood and plasma of site-targeted nanoparticle ultrasound contrast agent for molecular imaging. J Acoust Soc Am. 2005;117:964–72.CrossRefPubMedGoogle Scholar
  21. 21.
    Cai WB, Yang HL, Zhang J, Yin JK, Yang YL, Yuan LJ, et al. The optimized fabrication of nanobubbles as ultrasound contrast agents for tumor imaging. Sci Rep. 2015;5:13725.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Chen X, Conti PS, Moats RA. In vivo near-infrared fluorescence imaging of integrin alphavbeta3 in brain tumor xenografts. Cancer Res. 2004;64:8009–14.CrossRefPubMedGoogle Scholar
  23. 23.
    Chen Y, Zheng G, Zhang ZH, Blessington D, Zhang M, Li H, et al. Metabolism-enhanced tumor localization by fluorescence imaging: in vivo animal studies. Opt Lett. 2003;28:2070–2.CrossRefPubMedGoogle Scholar
  24. 24.
    Graves EE, Weissleder R, Ntziachristos V. Fluorescence molecular imaging of small animal tumor models. Curr Mol Med. 2004;4:419–30.CrossRefPubMedGoogle Scholar
  25. 25.
    Moon WK, Lin Y, O’Loughlin T, Tang Y, Kim DE, Weissleder R, et al. Enhanced tumor detection using a folate receptor-targeted near-infrared fluorochrome conjugate. Bioconjug Chem. 2003;14:539–45.CrossRefPubMedGoogle Scholar
  26. 26.
    Ntziachristos V, Ripoll J, Wang LV, Weissleder R. Looking and listening to light: the evolution of whole-body photonic imaging. Nat Biotechnol. 2005;23:313–20.CrossRefPubMedGoogle Scholar
  27. 27.
    Tung CH, Lin Y, Moon WK, Weissleder R. A receptor-targeted near-infrared fluorescence probe for in vivo tumor imaging. Chembiochem. 2002;3:784–6.CrossRefPubMedGoogle Scholar
  28. 28.
    Veiseh M, Gabikian P, Bahrami SB, Veiseh O, Zhang M, Hackman RC, et al. Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. Cancer Res. 2007;67:6882–8.CrossRefPubMedGoogle Scholar
  29. 29.
    Gao M, Yu F, Chen H, Chen L. Near-infrared fluorescent probe for imaging mitochondrial hydrogen polysulfides in living cells and in vivo. Anal Chem. 2015;87:3631–8.CrossRefPubMedGoogle Scholar
  30. 30.
    Hawrysz DJ, Sevick-Muraca EM. Developments toward diagnostic breast cancer imaging using near-infrared optical measurements and fluorescent contrast agents. Neoplasia. 2000;2:388–417.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Ntziachristos V, Bremer C, Weissleder R. Fluorescence imaging with near-infrared light: new technological advances that enable in vivo molecular imaging. Eur Radiol. 2003;13:195–208.PubMedGoogle Scholar
  32. 32.
    Yi X, Yan F, Wang F, Qin W, Wu G, Yang X, et al. IR-780 dye for near-infrared fluorescence imaging in prostate cancer. Med Sci Monit. 2015;21:511–7.CrossRefPubMedPubMedCentralGoogle Scholar
  33. 33.
    Svoboda M, Riha J, Wlcek K, Jaeger W, Thalhammer T. Organic anion transporting polypeptides (OATPs): regulation of expression and function. Curr Drug Metab. 2011;12:139–53.CrossRefPubMedGoogle Scholar
  34. 34.
    Shitara Y, Maeda K, Ikejiri K, Yoshida K, Horie T, Sugiyama Y. Clinical significance of organic anion transporting polypeptides (OATPs) in drug disposition: their roles in hepatic clearance and intestinal absorption. Biopharm Drug Dispos. 2013;34:45–78.CrossRefPubMedGoogle Scholar
  35. 35.
    James NS, Ohulchanskyy TY, Chen Y, Joshi P, Zheng X, Goswami LN. Comparative tumor imaging and PDT Efficacy of HPPH conjugated in the mono- and di-forms to various polymethine 12cyanine dyes: part - 2. Theranostics. 2013;3:703–18.Google Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2016

Authors and Affiliations

  1. 1.Department of Ultrasound DiagnosisTang Du Hospital, Fourth Military Medical UniversityXi’anChina
  2. 2.Department of UrologyPLA 105 HospitalHefeiChina

Personalised recommendations